These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 25591514

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J, US01 Study Team.
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T, Ander L, Kolf K, Woitalla D, Muhlack S.
    J Neural Transm (Vienna); 2007 Oct; 114(11):1457-62. PubMed ID: 17564755
    [Abstract] [Full Text] [Related]

  • 45. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE, Thomas SK, Hagiwara M, Mancione L.
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [Abstract] [Full Text] [Related]

  • 46. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T.
    Clin Neuropharmacol; 2013 Jul; 36(3):84-91. PubMed ID: 23673910
    [Abstract] [Full Text] [Related]

  • 47. Istradefylline (Nourianz) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Feb 10; 62(1591):20-23. PubMed ID: 32022788
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P, Cote L, Fahn S.
    Adv Neurol; 1993 Feb 10; 60():703-6. PubMed ID: 8420214
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Levodopa: the story continues].
    Titova NV, Katunina EA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014 Feb 10; 114(9):93-9. PubMed ID: 25473661
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov 10; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 58. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
    Klostermann F, Bojarski C, Marzinzik F, Maier A, Schindlbeck KA, Ehlen F.
    Mov Disord; 2017 Feb 10; 32(2):300-301. PubMed ID: 27859611
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
    Rosenthal SH, Fenton ML, Harnett DS.
    Gen Hosp Psychiatry; 1992 Jul 10; 14(4):285-6. PubMed ID: 1505751
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.